
Peter Palese, PhD
- PROFESSOR & CHAIR | Microbiology
- PROFESSOR | Medicine, Infectious Diseases
Research Topics:
Antivirals, Apoptosis/Cell Death, Biodefense, Coronavirus, Influenza Virus, Interferon, Interferon Antagonists, Nipah Virus, Paramyxovirus, RNA, SARS Virus, Vaccine Development, Virulence Genes, Viruses and VirologyPalese Laboratory Website
http://labs.icahn.mssm.edu/paleselab/
Wikipedia
Visit Dr. Palese's Wikipedia page
Video
Watch a video featuring the Microbiology and Virology Ph.D. Graduate School Program.
Videos
Multi-Disciplinary Training Areas
Microbiology [MIC], Pharmacology and Therapeutics Discovery [PTD]Education
PhD, University of Vienna
-
2015
Beijerinck Virology Prize -
2014
Elected Fellow of the American Academy of Arts and Sciences -
2014
Honorary Doctorate -
2012
Sanofi–Institut Pasteur Award -
2012
Election to the Institute of Medicine of the National Academy of Sciences -
2010
European Virology Award (EVA) -
2006
Elected Member -
2006
Robert Koch Prize -
2002
Corresponding Member -
2000
Member
The Palese Laboratory focuses on fundamental questions concerning the genetic make-up and biology of viruses, as well as virus-host interactions. They use molecular biological techniques to understand how viruses replicate and how they interact with cells to cause disease in their hosts. Emphasis is on the study of RNA viruses, including influenza, paramyxo, and corona viruses. These are four major research directions in the laboratory at the present time: (1) by genetically changing influenza viruses via recombinant DNA techniques, they are studying viral genes and gene products to develop a universal influenza virus vaccine; (2) intracellular proteins are identified that interact with viral proteins, and the biological functions of these cellular proteins are studies; (3) attempts are made to develop broad spectrum antivirals and to identify their mechanisms of actions.
The Palese Laboratory is interested in training students and postdoctoral fellows who will become independent investigators in "molecular" studies of infectious viral diseases.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Palese during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Company Founder:
- Vaxalto
Consulting:
- Accurius; Anvateo Biosciences London; Avimex; Boehringer Ingelheim Corporation; Novavax; Opentrons Lab Works; Revelar; Vaxalto
Royalty Payments:
- Avimex; MedImmune, LLC
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.